Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Gary E. Raskob,Nick van Es,Peter Verhamme,Marc Carrier,Marcello Di Nisio,David A. Garcia,Michael A. Grosso,Ajay K. Kakkar,Michael J. Kovacs,Michele Mercuri,Guy Meyer,Annelise Segers,Minggao Shi,Tzu-Fei Wang,Erik Yeo,George Zhang,Jeffrey I. Zwicker,Jeffrey I. Weitz,Harry R. Büller +18 more
Reads0
Chats0
TLDR
Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding during the 12 months after randomization, regardless of treatment duration.Abstract:
Background Low-molecular-weight heparin is the standard treatment for cancer-associated venous thromboembolism. The role of treatment with direct oral anticoagulant agents is unclear. Methods In this open-label, noninferiority trial, we randomly assigned patients with cancer who had acute symptomatic or incidental venous thromboembolism to receive either low-molecular-weight heparin for at least 5 days followed by oral edoxaban at a dose of 60 mg once daily (edoxaban group) or subcutaneous dalteparin at a dose of 200 IU per kilogram of body weight once daily for 1 month followed by dalteparin at a dose of 150 IU per kilogram once daily (dalteparin group). Treatment was given for at least 6 months and up to 12 months. The primary outcome was a composite of recurrent venous thromboembolism or major bleeding during the 12 months after randomization, regardless of treatment duration. Results Of the 1050 patients who underwent randomization, 1046 were included in the modified intention-to-treat analys...read more
Citations
More filters
Journal ArticleDOI
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS)
Stavros Konstantinides,Guy Meyer,Cecilia Becattini,Héctor Bueno,Geert-Jan Geersing,Veli-Pekka Harjola,Menno V. Huisman,Marc Humbert,Catriona Jennings,David Jiménez,Nils Kucher,Irene M. Lang,Mareike Lankeit,Roberto Lorusso,Lucia Mazzolai,Nicolas Meneveau,Fionnuala Ní Áinle,Paolo Prandoni,Piotr Pruszczyk,Marc Philip Righini,Adam Torbicki,Eric Van Belle,José Luis Zamorano +22 more
TL;DR: Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition.
Journal ArticleDOI
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Jan Steffel,Peter Verhamme,Tatjana S. Potpara,Pierre Albaladejo,M Antz,Lien Desteghe,Karl Georg Haeusler,Jonas Oldgren,Holger Reinecke,Roldan-Schilling,Nigel Rowell,Peter Sinnaeve,Ronan Collins,Alan John Camm,Hein Heidbuchel +14 more
TL;DR: Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF) and have emerged as the preferred choice, particularly in patients newly started on antICOagulation.
Journal ArticleDOI
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) : The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)
Stavros Konstantinides,Guy Meyer,Cecilia Becattini,Héctor Bueno,Geert-Jan Geersing,Veli-Pekka Harjola,Menno V. Huisman,Marc Humbert,Catriona Jennings,David Jiménez,Nils Kucher,Irene M. Lang,Mareike Lankeit,Roberto Lorusso,Lucia Mazzolai,Nicolas Meneveau,Fionnuala Ní Áinle,Paolo Prandoni,Piotr Pruszczyk,Marc Philip Righini,Adam Torbicki,Eric Van Belle,José Luis Zamorano +22 more
TL;DR: New ESCardio Guidelines for the Diagnosis and Management of Acute PulmonaryEmbolism developed in collaboration with EuroRespSoc are available.
Journal ArticleDOI
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
Dominique Farge,Dominique Farge,Corinne Frere,Jean M. Connors,Cihan Ay,Alok A. Khorana,Andrés Muñoz,Benjamin Brenner,Ajay K. Kakkar,Hanadi Rafii,Susan Solymoss,Dialina Brilhante,Manuel Monreal,Henri Bounameaux,Ingrid Pabinger,James D. Douketis,Walter Ageno,Fernando Ajauro,Kamal R. Al-Aboudi,Thierry Alcindor,Thierry André,Pantep Angchaisuksiri,Darko Antic,Juan I. Arcelus,Eric Assenat,Kenneth A. Bauer,Ali Bazarbachii,I. Benzidia,Jan Beyer-Westendorf,Viktoria Bitsadze,Dorit Blickstein,Mark Blostein,Isabel Bogalho,Barbara Bournet,Patricia Casais,Antoine F. Carpentier,Gabriela Cesarman-Maus,Joydeep Chakbrabartty,Hugo A. Clemente,Jérôme Connault,Ludovic Doucet,Cécile Durant,Joseph Emmerich,Anna Falanga,Clemens Feistritzer,Carme Font,Charles W. Francis,Enrique Gallardo,Thomas Gary,Jean-Christophe Gris,Cecilia Guillermo,A. Hij,Russel D. Hull,Takayuki Ikezoe,Luis Jara-Palomares,Nigel S. Key,Jamilya Khrizroeva,Maral Koolian,Florian Langer,Ramón Lecumberri,Lai Heng Lee,Howard A. Liebman,Luisa Lopes Dos Santos,Duarte Henrique Machado,Isabelle Madelaine,Alexander Makatsariya,Mario Mandalà,Anthony Marayevas,Zora Marjanovic,Christine Marosi,Ellis Martin,Luis Meillon,Emmanuel Messas,Antonio Moreira,Ahmet M. Demir,Arlette Ndour,Michel Nguessan,Remedios Otero-Candelera,Vanessa Pachon Olmos,Ana Pais,Florian Posch,Matthias Preusser,Hanno Riess,Marc Philip Righini,Cynthia Rothschild,Andre Roussin,José Antonio Rueda-Camino,Pedro Ruiz-Artacho,Sanjith Saseedharan,Ali Shamseddine,Gerald A. Soff,Hans Stricker,Vicky Tagalakis,Ali T. Taher,Toutou Toussaint,Javier Trujillo-Santos,Stéphane Villiers,Raymond S.M. Wong,Norizaku Yamada +98 more
TL;DR: The 2019 International Initiative on Thrombosis and Cancer clinical practice guidelines, which are based on a systematic review of the literature published up to December, 2018, are presented along with a Grading of Recommendations Assessment Development and Evaluation scale methods.
Journal ArticleDOI
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Patrick Y. Wen,Michael Weller,Eudocia Q. Lee,Brian M. Alexander,Jill S. Barnholtz-Sloan,Floris P. Barthel,Tracy T. Batchelor,Ranjit S. Bindra,Susan M. Chang,E. Antonio Chiocca,Timothy F. Cloughesy,John DeGroot,Evanthia Galanis,Mark R. Gilbert,Monika E. Hegi,Craig Horbinski,Raymond Y. Huang,Andrew B. Lassman,Emilie Le Rhun,Michael Lim,Minesh P. Mehta,Ingo K. Mellinghoff,Giuseppe Minniti,David Nathanson,Michael Platten,Matthias Preusser,Patrick Roth,Marc Sanson,David Schiff,Susan C Short,Martin J B Taphoorn,Joerg C. Tonn,Jonathan Tsang,Roel G.W. Verhaak,Andreas von Deimling,Wolfgang Wick,Gelareh Zadeh,David A. Reardon,Kenneth Aldape,Martin J. van den Bent +39 more
TL;DR: Novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies and viral therapies will be reviewed, as well as the current challenges and future directions for research.
References
More filters
Journal ArticleDOI
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report
Clive Kearon,Elie A. Akl,Elie A. Akl,Joseph Ornelas,Allen J. Blaivas,David Jiménez,Henri Bounameaux,Menno V. Huisman,Christopher S. King,Timothy A. Morris,Namita Sood,Scott M. Stevens,Janine R.E. Vintch,Philip S. Wells,Scott C. Woller,Lisa K. Moores +15 more
TL;DR: Recommendations on 12 topics that were in the 9th edition of these guidelines are updated, and 3 new topics are addressed.
Journal ArticleDOI
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients: Definitions of major bleeding in clinical studies
S. Schulman,C. Kearon +1 more
TL;DR: A definition of major bleeding in non‐surgical patients was developed that should be applicable to studies with all agents that interfere with hemostasis, including anticoagulants, platelet function inhibitors and fibrinolytic drugs.
Journal ArticleDOI
Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
Agnes Y.Y. Lee,Mark Levine,Ross I. Baker,Chris Bowden,Ajay K. Kakkar,Martin H. Prins,Frederick R. Rickles,Jim A. Julian,Susan Haley,Michael J. Kovacs,Michael Gent +10 more
TL;DR: In patients with cancer and acute venous thromboembolism, dalteparin was more effective than an oral anticoagulant in reducing the risk of recurrent thrombosis without increasing therisk of bleeding.
Journal ArticleDOI
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.
Paolo Prandoni,Anthonie W. A. Lensing,Andrea Piccioli,Enrico Bernardi,Paolo Simioni,Bruno Girolami,Antonio Marchiori,Paola Sabbion,Martin H. Prins,Franco Noventa,Antonio Girolami +10 more
TL;DR: Possibility for improvement using the current paradigms of anticoagulation seem limited and new treatment strategies should be developed, as cancer patients with venous thrombosis are more likely to develop recurrent thromboembolic complications and major bleeding during anticoaggerant treatment than those without malignancy.
Journal ArticleDOI
Epidemiology of cancer-associated venous thrombosis
TL;DR: This review describes the literature on incidence of and risk factors for cancer-associated venous thrombosis to provide a basis for identification of high-risk patients and for further development and refinement of prediction models.